Clinical Trials Logo

KRAS G12C Mutant Solid Tumors clinical trials

View clinical trials related to KRAS G12C Mutant Solid Tumors.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06435455 Not yet recruiting - Clinical trials for KRAS G12C Mutant Solid Tumors

GH21 Combined With D-1553 With Advanced Solid Tumors

Start date: July 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This s a multi-center, open-label phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of GH21 combined with D-1553 in patients with advanced or metastatic solid tumors harboring KRAS G12C mutation.